Therapy-related AML after lung cancer is rare, but is associated with poor prognosis.
The approval was based on data from several clinical trials, including the phase 3 PACIFIC trial and the phase 3 CASPIAN trial.
Interim analysis shows risk for disease progression or death lower for first-line therapy with lorlatinib versus crizotinib.
Nicotine e-cigarettes added to counseling improved abstinence at 12 weeks, but not at 24 weeks.
Potential years of life lost per death highest for deaths due to cancers of testis, bones/joints, other endocrine sites.